Antibody-based Cancer Drugs
Developing Antibody Therapeutic approaches to deliver individualised cancer drugs
In the Chair:
Dr. Terje Kalland
Hear from your eminent Speaker Panel:
Dr. Geoffrey Davis
Professor Jan G. J. van de Winkel
Dr. Roland Carlsson
Dr. Hans de Haard
Dr. Associate Professor Göran Forsberg
Professor Peter Vollmers
Oncology is the most active area in the pharmaceutical community driven by cancer as the leading cause of death in Western countries. Antibodies hold most promise in the treatment of cancer. By exploring antibody therapeutic approaches the number of target pathways increases significantly.
The vision of cancer immunology is to find new approaches to fighting cancer by activating the human body’s immune defence system. With antibodies as drugs the immune systems are able to attack the antigens which are found on the surface of cancer cells. Innovative biopharmaceuticals who successfully creates targeted antibody therapies to improve cancer patients’ health will be the winners of the future.
We are quickly moving in the direction where it is possible to develop the right drug to match with the right cancer patient. In tomorrow’s Bio-Society individual cancer medicines will be a reality!
This international one day symposium will examine the role of antibodies as new drugs for cancer in the future. The event provides you with a platform to design new antibody approaches for individualised cancer drugs with first-hand experiences learnt from the pioneers of oncology in the 21st century.
Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Business Officers, Vice Presidents, Directors, Heads and Scientists within:
Official Airline & Hotel: